Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.